Jonathan Deeks is a UK National Institute for Health Research (NIHR) Senior Investigator Emeritus. The views expressed do not necessarily reflect the UK Government’s official policies. The editorial base of Cochrane Infectious Diseases is funded by UK aid from the UK Government for the benefit of low‐ and middle‐income countries (project number 300342‐104).
Thank you also to peer referees Trish Greenhalgh, Robert Walton, Chris Cates and Lynda Ware, consumer referee Jenny Negus, and methodological referees Gianni Virgili and Marta Roqué, for their insights. We thank Denise Mitchell for her efforts in copy‐editing this review. We thank Robin Featherstone for comments on the search and Mike Brown and Paul Garner for sign‐off comments. We thank Helen Wakeford, Anne‐Marie Stephani and Deirdre Walshe for their comments and editorial management. The editorial process for this review was managed by Cochrane's EMD Editorial Service in collaboration with Cochrane Infectious Diseases. Due to conflict of interest, a decision was taken to have a systematic reviewer, Nicholas Henschke, independently check all data extracted by her before publication. We would like to acknowledge Joanne Merckx for her contribution to the data extraction of nine papers in the initial stages of this review. We thank Dr Jane Cunningham (World Health Organization) for participation in technical discussions and comments on the manuscript. The wider team of systematic reviewers from University of Birmingham, UK who assisted with title and abstract screening across the entire suite of reviews for the diagnosis of COVID‐19 (Agarwal R, Baldwin S, Berhane S, Herd C, Kristunas C, Quinn L, Scholefield B). Imaging tests (Salameh JP, McGrath TA, van der Pol CB, Frank RA, Prager R, Hare SS, Dennie C, Jenniskens K, Korevaar DA, Cohen JF, van de Wijgert J, Damen JAAG, Wang J) Routine laboratory markers (Yang B, Langendam M, Ochodo E, Guleid F, Holtman G, Verbakel J, Wang J, Stegeman I) Signs and symptoms (Stuyf T, Domen J, Horn S) Molecular, antigen, and antibody tests (Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris I, Price M, Taylor‐Phillips S) The systematic review teams for each review: The project team (Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MMG, Spijker R, Hooft L, Van den Bruel A, McInnes MDF, Emperador D, Dittrich S) Members of the Cochrane COVID‐19 Diagnostic Test Accuracy Review Group include: These studies are for diagnostic products developed by private sector companies who provide access to know‐how, equipment/reagents, and contribute through unrestricted donations as per FIND policy and external SAC review. It is FIND’s role to accelerate access to high quality diagnostic tools for low resource settings and this is achieved by supporting both R&D and access activities for a wide range of diseases, including COVID‐19.FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. FIND is a global non‐for profit product development partnership and WHO Diagnostic Collaboration Centre. Sabine Dittrich: is employed by FIND with funding from DFID and Australian Aid. FIND has several clinical research projects to evaluate multiple new diagnostic tests against published Target Product Profiles that have been defined through consensus processes. In no situation, the commissioner had any influence on the results of the work.ĭevy Emperador: is employed by FIND. René Spijker: the Dutch Cochrane Centre (DCC) has received grants for performing commissioned systematic reviews.
0 kommentar(er)
